Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Behan FM, Iorio F, Picco G, Gonçalves E, Beaver CM, Migliardi G, Santos R, Rao Y, Sassi F, Pinnelli M, Ansari R, Harper S, Jackson DA, McRae R, Pooley R, Wilkinson P, van der Meer D, Dow D, Buser-Doepner C, Bertotti A, Trusolino L, Stronach EA, Saez-Rodriguez J, Yusa K, Garnett MJ.

Nature. 2019 Apr;568(7753):511-516. doi: 10.1038/s41586-019-1103-9. Epub 2019 Apr 10.

PMID:
30971826
2.

Structural rearrangements generate cell-specific, gene-independent CRISPR-Cas9 loss of fitness effects.

Gonçalves E, Behan FM, Louzada S, Arnol D, Stronach EA, Yang F, Yusa K, Stegle O, Iorio F, Garnett MJ.

Genome Biol. 2019 Feb 5;20(1):27. doi: 10.1186/s13059-019-1637-z.

3.

Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer.

Blagden SP, Hamilton AL, Mileshkin L, Wong S, Michael A, Hall M, Goh JC, Lisyanskaya AS, DeSilvio M, Frangou E, Stronach EA, Gopalakrishna P, Meniawy TM, Gabra H.

Clin Cancer Res. 2019 Mar 1;25(5):1472-1478. doi: 10.1158/1078-0432.CCR-18-2277. Epub 2018 Dec 18.

PMID:
30563934
4.

Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-1-regulated apoptosis in pancreatic cancer cells.

Burmi RS, Maginn EN, Gabra H, Stronach EA, Wasan HS.

Cancer Biol Ther. 2019;20(1):21-30. doi: 10.1080/15384047.2018.1504718. Epub 2018 Sep 27.

5.

Unsupervised correction of gene-independent cell responses to CRISPR-Cas9 targeting.

Iorio F, Behan FM, Gonçalves E, Bhosle SG, Chen E, Shepherd R, Beaver C, Ansari R, Pooley R, Wilkinson P, Harper S, Butler AP, Stronach EA, Saez-Rodriguez J, Yusa K, Garnett MJ.

BMC Genomics. 2018 Aug 13;19(1):604. doi: 10.1186/s12864-018-4989-y.

6.

Biomarker Assessment of HR Deficiency, Tumor BRCA1/2 Mutations, and CCNE1 Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy.

Stronach EA, Paul J, Timms KM, Hughes E, Brown K, Neff C, Perry M, Gutin A, El-Bahrawy M, Steel JH, Liu X, Lewsley LA, Siddiqui N, Gabra H, Lanchbury JS, Brown R.

Mol Cancer Res. 2018 Jul;16(7):1103-1111. doi: 10.1158/1541-7786.MCR-18-0034. Epub 2018 May 3.

7.

Dietary geranylgeraniol can limit the activity of pitavastatin as a potential treatment for drug-resistant ovarian cancer.

de Wolf E, Abdullah MI, Jones SM, Menezes K, Moss DM, Drijfhout FP, Hart SR, Hoskins C, Stronach EA, Richardson A.

Sci Rep. 2017 Jul 14;7(1):5410. doi: 10.1038/s41598-017-05595-4.

8.

MicroRNAs associated with small bowel neuroendocrine tumours and their metastases.

Miller HC, Frampton AE, Malczewska A, Ottaviani S, Stronach EA, Flora R, Kaemmerer D, Schwach G, Pfragner R, Faiz O, Kos-Kudła B, Hanna GB, Stebbing J, Castellano L, Frilling A.

Endocr Relat Cancer. 2016 Sep;23(9):711-26. doi: 10.1530/ERC-16-0044. Epub 2016 Jun 27.

9.

Preventing Damage Limitation: Targeting DNA-PKcs and DNA Double-Strand Break Repair Pathways for Ovarian Cancer Therapy.

Dungl DA, Maginn EN, Stronach EA.

Front Oncol. 2015 Oct 26;5:240. doi: 10.3389/fonc.2015.00240. eCollection 2015. Review.

10.

A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway.

Cheraghchi-Bashi A, Parker CA, Curry E, Salazar JF, Gungor H, Saleem A, Cunnea P, Rama N, Salinas C, Mills GB, Morris SR, Kumar R, Gabra H, Stronach EA.

Oncotarget. 2015 Dec 8;6(39):41736-49. doi: 10.18632/oncotarget.6153.

11.

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.

Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC Jr, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, Edmondson R, Fotopoulou C, Gabra H, Galon J, Gourley C, Heong V, Huntsman DG, Iwanicki M, Karlan BY, Kaye A, Lengyel E, Levine DA, Lu KH, McNeish IA, Menon U, Narod SA, Nelson BH, Nephew KP, Pharoah P, Powell DJ Jr, Ramos P, Romero IL, Scott CL, Sood AK, Stronach EA, Balkwill FR.

Nat Rev Cancer. 2015 Nov;15(11):668-79. doi: 10.1038/nrc4019. Review.

12.

Dose-Finding Quantitative 18F-FDG PET Imaging Study with the Oral Pan-AKT Inhibitor GSK2141795 in Patients with Gynecologic Malignancies.

Gungor H, Saleem A, Babar S, Dina R, El-Bahrawy MA, Curry E, Rama N, Chen M, Pickford E, Agarwal R, Blagden S, Carme S, Salinas C, Madison S, Krachey E, Santiago-Walker A, Smith DA, Morris SR, Stronach EA, Gabra H.

J Nucl Med. 2015 Dec;56(12):1828-35. doi: 10.2967/jnumed.115.156505. Epub 2015 Oct 1.

13.

The role of interleukin-8 (IL-8) and IL-8 receptors in platinum response in high grade serous ovarian carcinoma.

Stronach EA, Cunnea P, Turner C, Guney T, Aiyappa R, Jeyapalan S, de Sousa CH, Browne A, Magdy N, Studd JB, Sriraksa R, Gabra H, El-Bahrawy M.

Oncotarget. 2015 Oct 13;6(31):31593-603. doi: 10.18632/oncotarget.3415.

14.

Modeling platinum sensitive and resistant high-grade serous ovarian cancer: development and applications of experimental systems.

Cunnea P, Stronach EA.

Front Oncol. 2014 Apr 17;4:81. doi: 10.3389/fonc.2014.00081. eCollection 2014. Review.

15.

Opportunities for translation: targeting DNA repair pathways in pancreatic cancer.

Maginn EN, de Sousa CH, Wasan HS, Stronach EA.

Biochim Biophys Acta. 2014 Aug;1846(1):45-54. doi: 10.1016/j.bbcan.2014.04.002. Epub 2014 Apr 13. Review.

PMID:
24727386
16.

Molecular subtypes of serous borderline ovarian tumor show distinct expression patterns of benign tumor and malignant tumor-associated signatures.

Curry EW, Stronach EA, Rama NR, Wang YY, Gabra H, El-Bahrawy MA.

Mod Pathol. 2014 Mar;27(3):433-42. doi: 10.1038/modpathol.2013.130. Epub 2013 Aug 16.

17.
18.

DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance.

Stronach EA, Chen M, Maginn EN, Agarwal R, Mills GB, Wasan H, Gabra H.

Neoplasia. 2011 Nov;13(11):1069-80.

19.

Rethinking ovarian cancer: recommendations for improving outcomes.

Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD, Balkwill FR.

Nat Rev Cancer. 2011 Sep 23;11(10):719-25. doi: 10.1038/nrc3144.

20.

HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer.

Stronach EA, Alfraidi A, Rama N, Datler C, Studd JB, Agarwal R, Guney TG, Gourley C, Hennessy BT, Mills GB, Mai A, Brown R, Dina R, Gabra H.

Cancer Res. 2011 Jul 1;71(13):4412-22. doi: 10.1158/0008-5472.CAN-10-4111. Epub 2011 May 13.

21.

Microarray coupled to quantitative RT-PCR analysis of androgen-regulated genes in human LNCaP prostate cancer cells.

Ngan S, Stronach EA, Photiou A, Waxman J, Ali S, Buluwela L.

Oncogene. 2009 May 14;28(19):2051-63. doi: 10.1038/onc.2009.68. Epub 2009 Apr 13.

PMID:
19363526
22.

Comparing the characteristics of gene expression profiles derived by univariate and multivariate classification methods.

Zucknick M, Richardson S, Stronach EA.

Stat Appl Genet Mol Biol. 2008;7(1):Article7. doi: 10.2202/1544-6115.1307. Epub 2008 Feb 23.

23.

Identification of clinically relevant genes on chromosome 11 in a functional model of ovarian cancer tumor suppression.

Stronach EA, Sellar GC, Blenkiron C, Rabiasz GJ, Taylor KJ, Miller EP, Massie CE, Al-Nafussi A, Smyth JF, Porteous DJ, Gabra H.

Cancer Res. 2003 Dec 15;63(24):8648-55.

24.

OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer.

Sellar GC, Watt KP, Rabiasz GJ, Stronach EA, Li L, Miller EP, Massie CE, Miller J, Contreras-Moreira B, Scott D, Brown I, Williams AR, Bates PA, Smyth JF, Gabra H.

Nat Genet. 2003 Jul;34(3):337-43.

PMID:
12819783
25.

BARX2 induces cadherin 6 expression and is a functional suppressor of ovarian cancer progression.

Sellar GC, Li L, Watt KP, Nelkin BD, Rabiasz GJ, Stronach EA, Miller EP, Porteous DJ, Smyth JF, Gabra H.

Cancer Res. 2001 Oct 1;61(19):6977-81.

26.

Novel PCR-based diagnostic tools for Charcot-Marie-Tooth type 1A and hereditary neuropathy with liability to pressure palsies.

Stronach EA, Clark C, Bell C, Löfgren A, McKay NG, Timmerman V, Van Broeckhoven C, Haites NE.

J Peripher Nerv Syst. 1999;4(2):117-22.

PMID:
10442687

Supplemental Content

Loading ...
Support Center